Therapeutic perspectives in atopic dermatitis

Clinical Reviews in Allergy and Immunology

Volumn 41, Issue 3, 2011, Pages 267-271

  Misery, Laurent ^a  

^a BREST UNIVERSITY HOSPITAL   (France)

Author keywords

Atopic dermatitis; Calcineurin; Immunity; Pruritus; Skin barrier; Treatment

Indexed keywords

ALEFACEPT; ANTIPRURITIC AGENT; ATOPICLAIR; AZATHIOPRINE; CALCITONIN GENE RELATED PEPTIDE; CYCLOSPORIN A; EFALIZUMAB; EMOLLIENT AGENT; EPICERAM; EXOMEGA; GAMMA INTERFERON; GLUCOCORTICOID; GLUCOSAMINE DERIVATIVE; INDOLEAMINE 2,3 DIOXYGENASE; INFLIXIMAB; INTERLEUKIN 10; MAPRACORAT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; N ACETYLGLUCOSAMINE PERACETYLATED 4 FLUORINATED DEXTRO GLUCOSAMINE; NONSTEROID ANTIINFLAMMATORY AGENT; OMALIZUMAB; PIMECROLIMUS; PROBIOTIC AGENT; RITUXIMAB; SUBSTANCE P ANTAGONIST; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZARZENDA;

ASTHMA; ATOPIC DERMATITIS; CLINICAL TRIAL (TOPIC); CONTACT ALLERGY; CORTICOSTEROID THERAPY; DRUG EFFICACY; DRUG FEVER; DRUG MEGADOSE; DRUG SAFETY; DYSPNEA; ECZEMA; FOAM; HUMAN; HYDROGEL; HYPERTRANSAMINASEMIA; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; MYALGIA; NONHUMAN; PHOTOTHERAPY; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PRURITUS; PSORIASIS; PSYCHOEDUCATION; REVIEW; SKIN ATROPHY; SKIN CARE;

B-LYMPHOCYTES; DERMATITIS, ATOPIC; HUMANS; IMMUNOGLOBULIN E; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; PROTEIN BINDING; RECEPTORS, GLUCOCORTICOID; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80054903480     PISSN: 10800549     EISSN: 15590267     Source Type: Journal    
DOI: 10.1007/s12016-010-8226-y     Document Type: Review

References (38)

1. CA Akdis M Akdis T Bieber C Bindslev-Jensen M Boguniewicz P Eigenmann, et al. 2006 Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report Allergy 61 969 987 16867052 10.1111/j.1398-9995.2006.01153.x 1:CAS:528:DC%2BD28XptVKis7c%3D (Pubitemid 44024897)
2. L Misery AY Finlay N Martin S Boussetta C Nguyen E Myon, et al. 2007 Atopic dermatitis: impact on the quality of life of patients and their partners Dermatology 215 123 129 17684374 10.1159/000104263 1:STN:280: DC%2BD2svmsFKmsw%3D%3D (Pubitemid 47230720)
3. L Misery 2005 Atopic dermatitis and psychological factors Ann Dermatol Venereol 132 S112 S115
4. J Arndt N Smith F Tausk 2008 Stress and atopic dermatitis Curr Allergy Asthma Rep 8 312 317 18606083 10.1007/s11882-008-0050-6 1:CAS:528: DC%2BD1cXoslOqu7s%3D
5. J Kupfer U Gieler TL Diepgen M Fartasch T Lob-Corzilius J Ring, et al. 2010 Structured education program improves the coping with atopic dermatitis in children and their parents-a multicenter, randomized controlled trial J Psychosom Res 68 353 358 20307702 10.1016/j.jpsychores.2009.04.014
6. D Staab TL Diepgen M Fartasch J Kupfer T Lob-Corzilius J Ring, et al. 2006 Age-related, structured educational programmes for the management of atopic dermatitis in children and adolescents: multicentre, randomised controlled trial BMJ 332 933 938 16627509 10.1136/bmj.332.7547.933
7. CM Gelbard AA Hebert 2008 New and emerging trends in the treatment of atopic dermatitis Patient Prefer Adherence 2 387 392 19920986
8. N Katoh 2009 Future perspectives in the treatment of atopic dermatitis J Dermatol 36 367 376 19583684 10.1111/j.1346-8138.2009.00662.x 1:CAS:528:DC%2BD1MXpslOhurk%3D
9. Elias PM, Wakefield J (2010) Therapeutic implications of a barrier-based pathogenesis of atopic dermatitis. Clinic Rev Allerg Immunol (in this issue)
10. R Grimalt V Mengeaud F Cambazard 2007 The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: a randomized controlled study Dermatology 214 61 67 17191050 10.1159/000096915 1:CAS:528: DC%2BD28XhtlCktLjF (Pubitemid 46033003)
11. J Sugarman L Parish 2009 Efficacy of a lipid-based, barrier repair formulation in moderate-to-severe pediatric atopic dermatitis J Drugs Dermatol 8 1106 1111 20027938
12. A Patrizi B Raone I Neri 2009 Atopiclair Expert Opin Pharmacother 10 1223 1230 10.1517/14656560902926106 1:CAS:528:DC%2BD1MXlt1SktLY%3D
13. JP Hachem T Roelandt N Schürer X Pu J Fluhr C Giddelo, et al. 2010 Acute acidification of stratum corneum membrane domains using polyhydroxyl acids improves lipid processing and inhibits degradation of corneodesmosomes J Invest Dermatol 130 500 510 19741713 10.1038/jid.2009.249 1:CAS:528: DC%2BC3cXntVanug%3D%3D
14. D Thaci R Salgo 2010 Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies Clin Dermatol 28 52 56 20082951 10.1016/j.clindermatol.2009.04.001
15. S Stander H Stander S Seeliger TA Luger M Steinhoff 2007 Topical pimecrolimus and tacrolimus transiently induce neuropeptide release and mast cell degranulation in murine skin Br J Dermatol 156 1020 1026 17388925 10.1111/j.1365-2133.2007.07813.x 1:STN:280:DC%2BD2s3kvFGmtw%3D%3D (Pubitemid 46642852)
16. U Pereira N Boulais N Lebonvallet JP Pennec G Dorange L Misery 2010 Mechanisms of sensory effects of tacrolimus on the skin Br J Dermatol 163 1 70 77 20302583 1:CAS:528:DC%2BC3cXhtVGitLfM
17. LB van der Aa HSA Heymans WMC van Aalderen AB Sprikkelman 2010 Probiotics and prebiotics in atopic dermatitis: review of the theoretical background and clinical evidence Pediatr Allergy Immunol 21 e355 e367 19573143 10.1111/j.1399-3038.2009.00915.x
18. H Schäcke M Berger H Rehwinkel K Asadullah 2007 Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index Mol Cell Endocrinol 275 109 117 17630119 10.1016/j.mce.2007. 05.014 (Pubitemid 47259282)
19. H Schäcke TM Zollner WD Döcke H Rehwinkel S Jaroch W Skuballa, et al. 2009 Characterization of ZK 245186, a novel, selective glucocorticoid receptor agonist for the topical treatment of inflammatory skin diseases Br J Pharmacol 158 1088 1103 19422381 10.1111/j.1476-5381.2009.00238.x
20. IG Jang JK Yang HJ Lee 2000 Clinical improvement and immunohistochemical findings in severe atopic dermatitis treated with interferon gamma J Am Acad Dermatol 42 1033 1040 10827410 10.1016/S0190-9622(00)90300-1 1:STN:280:DC%2BD3c3oslKhsA%3D%3D
21. LJ Meagher NY Wines AJ Cooper 2002 Atopic dermatitis: review of immunopathogenesis and advances in immunosuppressive therapy Australas J Dermatol 43 247 254 12423430 10.1046/j.1440-0960.2002.00610.x (Pubitemid 35365413)
22. A Jacobi C Antoni B Manger G Schuler M Hertl 2005 Infliximab in the treatment of moderate to severe atopic dermatitis J Am Acad Dermatol 52 522 526 15761436 10.1016/j.jaad.2004.11.022
23. RL Buka B Resh B Roberts BB Cunningham S Friedlander 2005 Etanercept is minimally effective in 2 children with atopic dermatitis J Am Acad Dermatol 53 358 359 16021144 10.1016/j.jaad.2005.03.013 (Pubitemid 40979606)
24. AC Davaine A Saraux S Prigent I Kupfer-Bessaguet D Roswag P Plantin, et al. 2008 Cutaneous events during treatment of chronic inflammatory joint disorders with anti-tumour necrosis factor alpha: a cross-sectional study J Eur Acad Dermatol Venereol 22 1471 1477 18713230 10.1111/j.1468-3083.2008.02935.x 1:STN:280:DC%2BD1M%2FkvVSqug%3D%3D
25. HH Lee IH Song M Friedrich A Gauliard J Detert J Rowert, et al. 2007 Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists Br J Dermatol 156 486 491 17300238 10.1111/j.1365-2133.2007.07682.x 1:CAS:528:DC%2BD2sXjvVKksLw%3D
26. CJ Dimitroff TS Kupper R Sackstein 2003 Prevention of leukocyte migration to inflamed skin with a novel fluorosugar modifier of cutaneous lymphocyte-associated antigen J Clin Invest 112 1008 1018 14523038 1:CAS:528:DC%2BD3sXnvFGrsLo%3D (Pubitemid 38056316)
27. EG Harper EL Simpson RH Takiguchi MD Boyd SE Kurtz AC Bakke, et al. 2008 Efalizumab therapy for atopic dermatitis causes marked increases in circulating effector memory CD4+ T cells that express cutaneous lymphocyte antigen J Invest Dermatol 128 1173 1181 18007580 10.1038/sj.jid.5701169 1:CAS:528: DC%2BD1cXksFyhsLs%3D (Pubitemid 351543209)
28. D Firmin AM Roguedas G Lemasson JF Abgrall L Misery 2008 Eczematous dermatosis and thrombocytosis induced by efalizumab: two new side effects Dermatology 217 203 206 18594143 10.1159/000141958 1:STN:280: DC%2BD1cnktF2mtg%3D%3D
29. D Simon J Wittwer G Kostylina U Buettiker HU Simon N Yawalkar 2008 Alefacept (lymphocyte function-associated molecule 3/IgG fusion protein) treatment for atopic eczema J Allergy Clin Immunol 122 423 424 18602679 10.1016/j.jaci.2008.06.010 1:CAS:528:DC%2BD1cXpsVGgsbo%3D
30. DK Moul SB Routhouska MR Robinson NJ Korman 2008 Alefacept for moderate to severe atopic dermatitis: a pilot study in adults J Am Acad Dermatol 58 984 989 18395294 10.1016/j.jaad.2008.02.007
31. D Simon S Hösli G Kostylina N Yawalkar HU Simon 2008 Anti-CD20 (rituximab) treatment improves atopic eczema J Allergy Clin Immunol 121 122 128 18206507 10.1016/j.jaci.2007.11.016 1:CAS:528:DC%2BD1cXovVyktw%3D%3D
32. CH Fanta 2009 Asthma N Engl J Med 360 1002 1014 19264689 10.1056/NEJMra0804579 1:CAS:528:DC%2BD1MXislyiurs%3D
33. RA Krathen S Hsu 2005 Failure of omalizumab for treatment of severe adult atopic dermatitis J Am Acad Dermatol 53 338 340 16021135 10.1016/j.jaad.2005. 02.014 (Pubitemid 40979597)
34. B Belloni M Ziai A Lim B Lemercier M Sbornik S Weidinger, et al. 2007 Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels J Allergy Clin Immunol 120 1223 1225 17936892 10.1016/j.jaci.2007.08.060 1:CAS:528:DC%2BD2sXht1Kkur3M (Pubitemid 350047479)
35. JE Lane JM Cheyney TN Lane DE Kent DJ Cohen 2006 Treatment of recalcitrant atopic dermatitis with omalizumab J Am Acad Dermatol 54 68 72 16384758 10.1016/j.jaad.2005.09.030 (Pubitemid 41832460)
36. LE Sheinkopf AW Rafi LT Do RM Katz WB Klaustermeyer 2008 Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study Allergy Asthma Proc 29 530 537 18926061 10.2500/aap.2008.29.3160 1:CAS:528:DC%2BD1cXht1KqtrfE
37. Misery L. (2010) Atopic dermatitis and the nervous system. Clinic Rev Allerg Immunol. doi: 10.1007/s12016-010-8225-z
38. Darsow U, Pfab F, Valet V, Huss-Marp J, Behrendt H, Ring J et al (2010) Pruritus and atopic dermatitis. Clinic Rev Allerg Immunol. doi: 10.1007/s12016-010-8230-2